Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (101)	5/5/2000 5:07:00 PM
From: nigel bates	Respond to of 625

They (Biovation) have a proteomics effort too - "A vast number of genomics technologies have been developed to try to link genes with disease for the discovery of novel drug targets. However, it is clear that although protein sequence can be deduced from a given gene sequence, expressed protein levels do not always correlate with mRNA levels. Moreover, differential splicing of mRNA's and post-translational modifications cannot be predicted by genomic analysis. It is for these reasons that Biovation is developing the high throughput BiodisplayTM technology to rapidly interrogate and profile proteins in human cells and tissue. Biovation's BioDisplayTM technology is designed to rapidly interrogate and profile proteins in large proteomes such as human cells and tissue. The technology uses arrays of antibodies which selectively bind to proteins from a mixture. Proteins absorbed by the antibody arrays are then analysed either by mass spectrometry. The technology is especially useful in identifying differences between cell or tissue samples such as normal versus disease. This can lead to the identification of drug targets. Once a protein of interest is identified, its corresponding antibody can be retrieved and used to monitor protein expression or modification in a range of cell or tissue samples. Biovation has initially established programmes to discover protein modifications and binding interactions which correlate with CNS diseases. Novel protein modifications are being subject to patent applications in order to provide exclusivity at the level of the target prior to screening for proprietary new drugs. A further programme in cancer is being initiated. Biovation is seeking partners for the further application and exploitation of its proteomics technologies. Two types of partnerships are sought, firstly where the partner has discovered disease-associated genes which require proteomics assays in order to determine the potential of the gene products as disease targets. Secondly, partnerships are being sought in specific disease areas for Biovation to apply its proteomics technologies in order to discover new targets. As Biovation's own programmes progress, the Company anticipates the formation of partnerships to assist in exploitation of proprietary targets including screening with pharmaceutical libraries."